Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 2;31(9):5151-5163.
doi: 10.3390/curroncol31090381.

Factors Influencing Outcomes and Survival in Anal Cancer

Affiliations

Factors Influencing Outcomes and Survival in Anal Cancer

Hugo C Temperley et al. Curr Oncol. .

Abstract

Background: We aim to ascertain prognostic factors in the current management of anal cancer within this study.

Methods: We reviewed the management and outcomes of anal cancer cases over a seven-year period, inclusive (2016-2023). The primary objectives were to assess the demographic characteristics, clinical presentation, and outcomes of all anal cancer patients within our institution. Kaplan-Meier survival analysis was used to estimate survival differences between cohorts, with statistical significance determined using log-rank testing. Cox proportional hazards regression was utilised to identify prognostic factors. Cox regression hazard ratios were reported along with confidence intervals and p-values.

Results: The median follow-up time for the study was 29.8 months. Seventy-five patients with anal cancer were included in this study, with 88% (66/75) being squamous cell carcinoma (SCC) and the majority having regional disease (82.7% (62/75)). The median age at diagnosis was 63.4 years (36-94). There was a female preponderance (57.3% (43/75)). In total, 84% (63/75) underwent definitive chemoradiation (dCRT), with 7/63 (11.1%) requiring a salvage abdomino-perineal resection (APR) for residual or recurrent disease. Adverse prognostic indicators include those with T4 disease hazard ratio = 3.81, (95% CI 1.13-12.83, * p = 0.04), poorly differentiated tumour disease HR = 3.37, (95% CI 1.13-10.02, * p = 0.04), having N2 nodal status HR = 5.03, (95% CI 1.11-22.8, * p = 0.04), and having metastatic disease at diagnosis HR = 5.8, (95% CI 1.28-26.42, * p = 0.02).

Conclusion: Presenting characteristics including stage, nodal, and differentiation status remain key prognostic indicators in those diagnosed with anal malignancy.

Keywords: anal cancer; oncological outcomes; recurrence; salvage surgery; survival; treatment response.

PubMed Disclaimer

Conflict of interest statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
(A) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for nodal status. (B) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for poor histological differentiation. (C) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for T4 tumour stage. (D) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for metastasis at diagnosis.
Figure 1
Figure 1
(A) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for nodal status. (B) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for poor histological differentiation. (C) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for T4 tumour stage. (D) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for metastasis at diagnosis.
Figure 1
Figure 1
(A) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for nodal status. (B) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for poor histological differentiation. (C) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for T4 tumour stage. (D) Kaplan–Meier Survival Curves (Log-Rank Test Results (p < 0.05)) for metastasis at diagnosis.

References

    1. Gondal T.A., Chaudhary N., Bajwa H., Rauf A., Le D., Ahmed S. Anal Cancer: The Past, Present and Future. Curr. Oncol. 2023;30:3232–3250. doi: 10.3390/curroncol30030246. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Lam A.K., Goldblum J.R. Tumours of the anal canal: Introduction. In: WHO Classification of Tumours Editorial Board, editor. WHO Classification of Tumours: Digestive System Tumours. 5th ed. International Agency for Research on Cancer; Lyon, France: 2019.
    1. Young A.N., Jacob E., Willauer P., Smucker L., Monzon R., Oceguera L. Anal Cancer Anal cancer Squamous cell carcinoma Anal canal Adenocarcinoma. Surg. Clin. North Am. 2020;100:629–634. doi: 10.1016/j.suc.2020.02.007. - DOI - PubMed
    1. Lin C., Franceschi S., Clifford G.M. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A systematic review and meta-analysis. Lancet Infect. Dis. 2018;18:198–206. doi: 10.1016/S1473-3099(17)30653-9. - DOI - PMC - PubMed